RANK, RANKL and osteoprotegerin in bone biology and disease

被引：276

作者：

Wright H.L. ^{[1
]}

McCarthy H.S. ^{[2
]}

Middleton J. ^{[1
]}

Marshall M.J. ^{[2
]}

机构：

[1] ISTM, Medical School, Keele University at the Leopold Muller Arthritis Research Centre, RJAH Orthopaedic Hospital, Oswestry

[2] Charles Salt Research Centre, RJAH Orthopaedic Hospital, Oswestry

来源：

Current Reviews in Musculoskeletal Medicine | 2009年 / 2卷 / 1期

关键词：

Disease; Osteoprotegerin (OPG); Receptor-activator of nuclear factor kappa beta (RANK); Receptor-activator of nuclear factor kappa beta ligand (RANKL); Review; Structure;

D O I：

10.1007/s12178-009-9046-7

中图分类号：

学科分类号：

摘要：

Upon the discovery of RANK, RANKL and OPG in the late 1990s, their importance in the maintenance of the skeletal structure and their dramatic role in bone disease were largely unexpected. In recent years the understanding of these proteins, in particular their regulation, has greatly increased. This review aims to bring the interested reader up to date with the latest news and views on the mechanisms controlling bone resorption in normal and pathological conditions.

引用

页码：56 / 64

页数：8

共 70 条

[1]

Stejskal D., Bartek J., Pastorkova R., Ruzicka V., Oral I., Horalik D., Osteoprotegerin, RANK, RANKL, Biomed Papers, 145, pp. 61-4, (2001)

[2]

Anderson D.M., Maraskovsky E., Billingsley W.L., Dougall W.C., Tometsko M.E., Roux E.R., Teepe M.C., DuBose R.F., Cosman D., Galibert L., A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function, Nature, 390, 6656, pp. 175-179, (1997)

[3]

Hofbauer L.C., Heufelder A.E., Osteoprotegerin-ligand und osteoprotegerin: Neue konzepte in der pathogenese und therapie metabolischer knochenerkrankungen, Deutsche Medizinische Wochenschrift, 126, 6, pp. 145-150, (2001)

[4]

Mosheimer B.A., Kaneider N.C., Feistritzer C., Djanani A.M., Sturn D.H., Patsch J.R., Wiedermann C.J., Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes, Journal of Clinical Endocrinology and Metabolism, 90, 5, pp. 2964-2971, (2005)

[5]

Kong Y.-Y., Yoshida H., Sarosi I., Tan H.-L., Timms E., Capparelli C., Morony S., Oliveira-dos-Santos A.J., Van G., Itie A., Khoo W., Wakeham A., Dunstan C.R., Lacey D.L., Mak T.W., Boyle W.J., Penninger J.M., OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis, Nature, 397, 6717, pp. 315-323, (1999)

[6]

Fata J.E., Kong Y.Y., Li J., Sasaki T., Irie-Sasaki J., Moorehead R.A., Elliott R., Scully S., Voura E.B., Lacey D.L., Boyle W.J., Khokha R., Penninger J.M., The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development, Cell, 103, pp. 41-50, (2000)

[7]

Kim N.-S., Kim H.-J., Koo B.-K., Kwon M.-C., Kim Y.-W., Cho Y., Yokota Y., Penninger J.M., Kong Y.-Y., Receptor activator of NF-κB ligand regulates the proliferation of mammary epithelial cells via Id2, Molecular and Cellular Biology, 26, 3, pp. 1002-1013, (2006)

[8]

Chen G., Sircar K., Aprikian A., Potti A., Goltzman D., Rabbani S.A., Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation, Cancer, 107, 2, pp. 289-298, (2006)

[9]

Hofbauer L.C., Osteoprotegerin ligand and osteoprotegerin: Novel implications for osteoclast biology and bone metabolism, European Journal of Endocrinology, 141, 3, pp. 195-210, (1999)

[10]

Heijne G.V., Life and death of a signal peptide, Nature, 396, pp. 111-3, (1998)

← 1 2 3 4 5 6 7 →